

Special Issue

Improving HPV Vaccination Coverage: Current Issues, Future Prospects and Strategies

Message from the Guest Editor

Globally, cervical cancer ranks as the fourth most common cancer and fourth leading cause of cancer death in women. According to the International Agency for Research on Cancer, Human papillomavirus (HPV) is considered carcinogenic to humans, particularly for cervix uteri. Countries are reporting a 65–97% reduction in the occurrence of cervical cancer in the population of vaccinated women, but disparities in cervical cancer burden will likely widen with differences in HPV vaccination coverage. According to the latest WHO data, globally in 2022 the HPV vaccination program coverage in females was 21% with the first dose and 15% with the last dose, while in males the coverage was 6% and 5%, respectively, with coverage varying more than 20-fold between WHO regions. In response to this, WHO updated recommendations for the HPV vaccination schedule. Improving HPV vaccination coverage is essential in reducing the burden of HPV-related cancers and health inequities. The COVID-19 pandemic has significantly disrupted HPV vaccination worldwide. This Special Issue is focused on current issues, future prospects and strategies aimed at improving HPV vaccination coverage.

Guest Editor

Dr. Irena Ilic

Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Deadline for manuscript submissions

28 February 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/187074

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).